therapeutic potential of mesenchymal stem cells for the treatment of airway remodeling in pulmonary diseases

according to significant improvements in the tissue engineering field over the past several years, lung tissue cells have recently attracted more attention due to the high prevalence and diversity in related diseases. however, selection of an appropriate cell type, screening of suitable conditions for growth and proliferation, as well as subsequent implantation into the body to repair and regenerate damaged tissues are considered as important issues in this context. it should also be noted that most studies have been described in animal models, but not in humans. because of the high regenerative capacity, predominant immunomodulatory feature, and inhibition of t-lymphocyte proliferation, mesenchymal stem cells (mscs) may play an important role in the reconstruction of damaged tissues including bronchioles in pulmonary diseases. interestingly, clinical trial studies demonstrated that mscs have the significant potential to treat a wide variety of diseases including acute myocardial infarction (ami), liver cirrhosis, crohn’s disease, and graft-versus-host disease (gvhd).